Preclinical Evaluation of Novel Combination Therapies Using Multigenic Humanized Models

Time: 4:50 pm
day: Day One


  • Introduce the use and advantages of humanized syngeneic mouse tumor models for evaluating preclinical efficacy, toxicity, and other mechanisms of action of antibody/biologic combination therapies
  • Outline the use of cell lines expressing tumor-associated antigens to evaluate dual checkpoint and TAA blockade in immune-checkpoint humanized mice
  • Describe the applicability of human immune system humanized mice, which includes highly immunodeficient (B-NDG) mice and second-generation B-NDG models with humanized cytokines to support human immune cell subpopulations, for evaluating immunotherapies against human tumor cells